Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oscotec Inc. (039200.KQ)
Seongnam-si, KR
Oscotec Inc. is a biopharmaceutical company specializing in the discovery and development of novel therapeutic drugs. Its primary focus lies in advancing a pipeline of investigational medicines, including a SYK inhibitor currently in Phase IIa clinical trials for the treatment of both rheumatoid arthritis and immune thrombocytopenia. Another key asset is an FLT3 inhibitor, undergoing Phase I clinical evaluation for acute myeloid leukemia. The company is also developing an EGFR double mutation inhibitor aimed at non-small cell lung cancer, and an Anti-Tau antibody in the preclinical stage for Alzheimer's disease. Beyond its pharmaceutical endeavors, Oscotec Inc. diversifies its offerings with a range of dental health products, such as bone graft materials like InduCera, BioCera-F, and SynCeraII, alongside membranes including LysoGide and CollaGuide. Additionally, it markets functional ingredients designed to address specific health concerns, such as OPB for osteoporosis, AIF for arthritis, SGA for enhancing bone growth, and PRF-K for periodontal conditions. Established in 1988, the company, originally known as Oscotec Co., Ltd, adopted its current name, Oscotec Inc., in June 1999. It is headquartered in Seongnam, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.73% | -20.23% | -29.34% | -31.71% | -21.60% | -10.74% | +44.22% | +59.71% | +9.03% | +359.65% | +502.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+193.6% ★ Q1'26: +88.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+5,870.2% ★ Q1'26: +54.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%-0.6% Q1'26: +1,303.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+55.1% ★ Q1'26: -273.8% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+58.1% ★ Q1'26: -97.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.0% Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.29× ★ Q1'26: -0.44× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
18.34B
est: 17.00B (+7.9%)
|
3.55B
est: 21.00B (-83.1%)
|
3.91B
est: 4.30B (-9.1%)
|
18.70B
est: 29.00B (-35.5%)
|
43.47B
est: 44.80B (-3.0%)
|
3.90B
est: 4.21B (-7.2%)
|
5.06B
est: 5.20B (-2.7%)
|
4.95B
est: 5.00B (-1.0%)
|
34.01B
est: 33.00B (+3.1%)
|
99.84B
est: 68.00B (+46.8%)
|
84.00B
66.32B – 101.68B
+23.5% YoY
|
192.00B
128.00B – 256.00B
+128.6% YoY
|
| EBITDA |
1.19B
est: -9.77B (+112.2%)
|
-6.26B
est: -12.07B (+48.1%)
|
-5.57B
est: -2.47B (-125.3%)
|
6.78B
est: -16.67B (+140.7%)
|
3.07B
est: -25.74B (+111.9%)
|
-27.02B
est: -2.42B (-1,017.6%)
|
-26.03B
est: -2.99B (-770.5%)
|
-30.02B
est: -2.87B (-944.8%)
|
1.91B
est: -15.88B (+112.0%)
|
53.71B
est: -32.72B (+264.2%)
|
-40.42B
-48.93B – -31.91B
-23.5% YoY
|
-92.39B
-123.18B – -61.59B
-128.6% YoY
|
| EBIT |
972.32M
est: -10.05B (+109.7%)
|
-4.15B
est: -12.41B (+66.5%)
|
-5.90B
est: -2.54B (-132.0%)
|
6.47B
est: -17.14B (+137.8%)
|
2.00B
est: -26.48B (+107.6%)
|
-28.48B
est: -2.49B (-1,045.4%)
|
-27.67B
est: -3.07B (-799.8%)
|
-31.88B
est: -2.95B (-978.8%)
|
-32.54M
est: -16.35B (+99.8%)
|
55.06B
est: -33.70B (+263.4%)
|
-41.63B
-50.39B – -32.86B
-23.5% YoY
|
-95.15B
-126.86B – -63.43B
-128.6% YoY
|
| Net Income |
395.03M
est: -3.80B (+110.4%)
|
-3.65B
est: 4.17B (-187.5%)
|
-5.86B
est: -3.36B (-74.2%)
|
3.47B
est: 11.73B (-70.4%)
|
-4.36B
est: 9.79B (-144.5%)
|
-26.26B
est: -42.90B (+38.8%)
|
-24.43B
est: -27.64B (+11.6%)
|
-24.28B
est: -23.60B (-2.9%)
|
876.53M
est: 344.32M (+154.6%)
|
52.55B
est: 22.51B (+133.4%)
|
24.45B
17.76B – 31.14B
+8.6% YoY
|
95.42B
11.82B – 179.02B
+290.3% YoY
|
| SGA |
1.70B
est: 15.71B (-89.2%)
|
654.07M
est: 19.41B (-96.6%)
|
1.28B
est: 3.97B (-67.7%)
|
1.20B
est: 26.80B (-95.5%)
|
5.71B
est: 41.40B (-86.2%)
|
5.54B
est: 3.89B (+42.5%)
|
6.22B
est: 4.81B (+29.3%)
|
8.47B
est: 4.62B (+83.3%)
|
4.45B
est: 30.12B (-85.2%)
|
7.46B
est: 62.07B (-88.0%)
|
76.68B
60.54B – 92.82B
+23.5% YoY
|
175.27B
116.84B – 233.69B
+128.6% YoY
|
| EPS |
15.85
est: -99.38 (+115.9%)
|
-137.32
est: 108.93 (-226.1%)
|
-211.09
est: -87.91 (-140.1%)
|
121.64
est: 306.72 (-60.3%)
|
-142.54
est: 256.08 (-155.7%)
|
-827.37
est: -1,121.73 (+26.2%)
|
-763.19
est: -722.63 (-5.6%)
|
-635.00
est: -617.00 (-2.9%)
|
22.92
est: 9.00 (+154.7%)
|
1,368.38
est: 588.50 (+132.5%)
|
639.00
464.12 – 813.88
+8.6% YoY
|
2,494.00
308.85 – 4,679.15
+290.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-15 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hirose Dakashi | Executive Officer | — | — |
| Jae-Sang Lee | Executive Officer | — | — |
| Jeung-Keun Kim | Chief Executive Officer | — | male |
| Ju-Won Kim | Executive Officer | — | — |
| Se-Nyun Kim | Executive Officer | — | — |
| Seung-Chul Lee | Executive Officer | — | — |
| So-Jin Ahn | Executive Officer | — | — |
| Su-Sung Lee | Executive Officer | — | — |
| Sung-Hee Son | Executive Officer | — | — |
| Sung-Ho Park | Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 039200.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
